Somatic mutation patterns and compound response in cancers

키워드

참고문헌 (36)

1. Blagosklonny, M. V., "Analysis of FDA approved anticancer drugs reveals the future of cancer therapy", Cell Cycle, 3, pp.1035~1042 (2004)
2. Kim, N., "Systematic analysis of genotype-specific drug responses in cancer", Int. J. Cancer, 131, pp.2456~2464 (2012)
3. Scudiero, D. A., "Evaluation of a soluble tetrazolium", formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines, 1988, pp.48, 4827~4833
4. Kwei, K. A., "Modulators of Sensitivity and Resistance to Inhibition of PI3K Identified in a Pharmacogenomic Screen of the NCI-60 Human Tumor Cell Line Collection", PLoS One, 7, pp.e46518~ (2012)
5. Blower, P. E., "MicroRNA expression profiles for the NCI-60 cancer cell panel", Mol. Cancer Ther, 6, pp.1483~1491 (2007)
6. Sausville, E. A., "Transcription profiling of gene expression in drug discovery and development: the NCI experience", Eur. J. Cancer, 40, pp.2544~2549 (2004)
7. Garraway, L. A., "Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma", Nature, 436, pp.117~122 (2005)
8. Blower, P. E., "MicroRNA expression profiles for the NCI-60 cancer cell panel", Mol. Cancer Ther, 6, pp.1483~1491 (2007)
9. Ikediobi, O. N., "Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.", Mol. Cancer Ther, 5, pp.2606~2612 (2006)
10. Nishizuka, S., "Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays", Proc. Natl. Acad. Sci. U.S.A, 100, pp.14229~14234 (2003)
11. Ehrich, M., "Cytosine methylation profiling of cancer cell lines", Proc. Natl. Acad. Sci. U.S.A, 105, pp.4844~4849 (2008)
12. Lee, J. S., "Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen", Mol. Pharmacol, 46, pp.627~638 (1994)
13. Shankavaram, U. T., "Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study", Mol. Cancer Ther, 6, pp.820~832 (2007)
14. Lee, A. C., "Data mining the NCI60 to predict generalized cytotoxicity", J. Chem. Inf. Model, 48, pp.1379~1388 (2008)
15. Clavel, J., "Progress in the epidemiological understanding of gene-environment interactions in major diseases: cancer", C. R. Biol, 330, pp.306~317 (2007)
16. Malumbres, M., "Cyclins and related kinases in cancer cells", J. BUON, 12(Suppl 1), pp.S45~S52 (2007)
17. Crow, R. T., "Landomycin A inhibits DNA synthesis and G1", S cell cycle progression, 1999, pp.9, 1663~1666
18. Yong-Joo Ahn, "AMP-activated protein kinase: implications on ischemic diseases", BMB Reports, 45(9), pp.489~495 (2012), 생화학분자생물학회
19. Keshavarz, P., "Single nucleotide polymorphisms in genes encoding LKB1 (STK11), TORC2 (CRTC2) and AMPK alpha2-subunit (PRKAA2) and risk of type 2 diabetes", Mol. Genet. Metab, 93, pp.200~209 (2008)
20. Uslu, R., "Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum", Cancer, 77, pp.725~732 (1996)
21. Zhang, Z., "Acetyl-l-carnitine inhibits TNF-alpha-induced insulin resistance via AMPK pathway in rat skeletal muscle cells", Febs. Lett, 583, pp.470~474 (2009)
22. Bonadona, V., "Cancer risks associated with germline mutations in MLH1, MSH2 and MSH6 genes in Lynch syndrome", JAMA, 305, pp.2304~2310 (2011)
23. Konstantinova, L. S., "One-pot synthesis of 5-phenylimino, 5-thieno or 5-oxo-1,2,3-dithiazoles and evaluation of their antimicrobial and antitumor activity", Bioorg. Med. Chem. Lett, 19, pp.136~141 (2009)
24. Lopez-Knowles, E., "Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients", Cancer Epidemiol. Biomarkers Prev, 19, pp.301~309 (2010)
25. Evidente, A., "Biological evaluation of structurally diverse amaryllidaceae alkaloids and their synthetic derivatives: discovery of novel leads for anticancer drug design", Planta Med, 75, pp.501~507 (2009)
26. Davies, H., "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
27. Alonso, C. M, "BRAF V600E mutation in adult acute lymphoblastic leukemia", Leuk. Lymphoma (2012)
28. Ikediobi, O. N., "In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation", Mol. Cancer Ther, 7, pp.1337~1346 (2008)
29. Ishihara, A., "Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance", Clin. Cancer Res, 1, pp.1035~1041 (1995)
30. Scott, S. A., "5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation", Leuk. Res, 30, pp.69~76 (2006)
31. Amatori, S., "Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma(MPM)cells", Lung Cancer, 66, pp.184~190 (2009)
32. Cheng, T., "Investigating the correlations among the chemical structures, bioactivity profiles and molecular targets of small molecules", Bioinformatics, 26, pp.2881~2888 (2010)
33. Kirchheiner, J., "Pharmacogenetics- based therapeutic recommendations- ready for clinical practice?", Nat. Rev. Drug Discov, 4, pp.639~647 (2005)
34. Altmann, A., "Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database", J. Infect. Dis, 199, pp.999~1006 (2009)
35. de Hoon, M. J., "Open source clustering software", Bioinformatics, 20, pp.1453~1454 (2004)
36. Eisen, M. B., "Cluster analysis and display of genome-wide expression patterns", Proc. Natl. Acad. Sci. U.S.A, 95, pp.14863~14868 (1998)

관련 논문AI추천